Published in Am J Respir Crit Care Med on May 18, 2006
Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste. BMJ (2009) 2.04
Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia. BMC Infect Dis (2011) 1.35
Nutritional status of adult patients with pulmonary tuberculosis in rural central India and its association with mortality. PLoS One (2013) 1.26
L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS One (2013) 1.20
Weight variation over time and its association with tuberculosis treatment outcome: a longitudinal analysis. PLoS One (2011) 1.00
Association of BMI category change with TB treatment mortality in HIV-positive smear-negative and extrapulmonary TB patients in Myanmar and Zimbabwe. PLoS One (2012) 0.92
Weight gain and response to treatment for multidrug-resistant tuberculosis. Am J Trop Med Hyg (2013) 0.89
Prognostic significance of early weight gain in underweight patients with tuberculosis. Am J Respir Crit Care Med (2006) 0.89
Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment. PLoS One (2013) 0.85
Assessment of serum calcium and phosphorus in pulmonary tuberculosis patients before, during and after chemotherapy. Indian J Clin Biochem (2013) 0.85
Low nutrient intake among adult women and patients with severe tuberculosis disease in Uganda: a cross-sectional study. BMC Public Health (2012) 0.84
Correlates of treatment outcomes and drug resistance among pulmonary tuberculosis patients attending tertiary care hospitals of Kolkata, India. PLoS One (2014) 0.84
Impaired pulmonary nitric oxide bioavailability in pulmonary tuberculosis: association with disease severity and delayed mycobacterial clearance with treatment. J Infect Dis (2013) 0.83
Head and Neck Tuberculosis: Scenario in a Tertiary Care Hospital of North Eastern India. J Clin Diagn Res (2016) 0.80
Undernutrition & tuberculosis in India: Situation analysis & the way forward. Indian J Med Res (2016) 0.80
Predictors of change in nutritional and hemoglobin status among adults treated for tuberculosis in Tanzania. Int J Tuberc Lung Dis (2011) 0.79
Serum PCT and its Relation to Body Weight Gain in Pulmonary Tuberculosis. Indian J Clin Biochem (2014) 0.79
A nested case-control study on relapse predictors among tuberculosis patients treated in Yemen's NTCP. Public Health Action (2012) 0.78
Tuberculosis outcomes in Papua, Indonesia: the relationship with different body mass index characteristics between papuan and non-Papuan ethnic groups. PLoS One (2013) 0.78
Factors Affecting Mortality and Treatment Completion of Tuberculosis Patients in Isfahan Province from 2006 to 2011. Int J Prev Med (2015) 0.77
Structural equation modeling of latent growth curves of weight gain among treated tuberculosis patients. PLoS One (2014) 0.75
Tuberculosis recurrence in a priority city in the state of São Paulo, Brazil. J Bras Pneumol (2017) 0.75
Cohort for Tuberculosis Research by the Indo-US Medical Partnership (CTRIUMPH): protocol for a multicentric prospective observational study. BMJ Open (2016) 0.75
Macronutrient intake and body composition changes during anti-tuberculosis therapy in adults. Clin Nutr (2015) 0.75
The combined fixed-dose antituberculous drugs alter some reproductive functions with oxidative stress involvement in wistar rats. Toxicol Rep (2016) 0.75
Risk of Sarcopenia and Osteoporosis in Male Tuberculosis Survivors: Korea National Health and Nutrition Examination Survey. Sci Rep (2017) 0.75
Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. BMJ Open (2017) 0.75
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep (2010) 8.16
Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep (2005) 6.45
Tuberculosis. Lancet (2003) 6.39
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Endothelial function in HIV-infected persons. Clin Infect Dis (2006) 3.80
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis (2007) 3.36
The effects of local review on informed consent documents from a multicenter clinical trials consortium. Control Clin Trials (2003) 3.30
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med (2009) 3.05
Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA (2002) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis (2002) 2.68
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med (2003) 2.56
Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr (2007) 2.53
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis (2012) 2.38
Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med (2011) 2.36
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis (2005) 2.34
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med (2006) 2.33
Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med (2014) 2.29
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med (2009) 2.18
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16
HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr (2005) 2.13
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis (2009) 2.04
Latent TB infection treatment acceptance and completion in the United States and Canada. Chest (2009) 1.97
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med (2009) 1.95
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med (2005) 1.85
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis (2005) 1.81
Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med (2007) 1.78
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis (2009) 1.72
Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin Infect Dis (2008) 1.72
Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin Infect Dis (2007) 1.69
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis (2003) 1.63
Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med (2014) 1.58
Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol (2010) 1.56
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis (2003) 1.53
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Epidemiology of tuberculosis in young children in the United States. Pediatrics (2014) 1.49
Use of a population-based survey to describe the health of Boston public housing residents. Am J Public Health (2007) 1.47
Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med (2006) 1.45
Evaluation of QuantiFERON-TB gold in-tube and tuberculin skin tests among immigrant children being screened for latent tuberculosis infection. Pediatr Infect Dis J (2015) 1.45
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother (2010) 1.45
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS (2012) 1.40
The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med (2003) 1.37
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis (2013) 1.37
Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis (2004) 1.36
Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol (2005) 1.34
The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. Drug Alcohol Depend (2008) 1.33
Environmental risk factors for infection with Mycobacterium avium complex. Am J Epidemiol (2006) 1.31
Black race, sex, and extrapulmonary tuberculosis risk: an observational study. BMC Infect Dis (2010) 1.29
Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS (2003) 1.28
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med (2010) 1.27
Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol (2013) 1.27
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother (2007) 1.26
Treatment of Tuberculosis. N Engl J Med (2015) 1.25
Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS (2008) 1.25
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med (2002) 1.23
Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis (2006) 1.21
Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother (2009) 1.19
Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr (2011) 1.19
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis (2006) 1.18
An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis (2011) 1.16
Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One (2013) 1.16
Integration of a participatory research strategy into a rural health survey. J Gen Intern Med (2003) 1.14
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis (2002) 1.14
Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis (2008) 1.14
CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther (2010) 1.13
Human immunodeficiency virus infection in a rural community in the United States. Am J Epidemiol (2004) 1.12
Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One (2013) 1.12
Diabetes, glycemic control, and risk of tuberculosis: a population-based case-control study. Diabetes Care (2011) 1.11
Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis (2004) 1.11
Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One (2011) 1.10
History of incarceration and gang involvement are associated with recent sexually transmitted disease/HIV diagnosis in African American men. J Acquir Immune Defic Syndr (2008) 1.09
Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States. South Med J (2002) 1.07
Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis (2014) 1.06